Long before it's time for hospice care, many people with serious illness can benefit from palliative care but don’t realize it. Sometimes referred to as “comfort care,” palliative care is a specialized approach to the treatment of patients with a serious or life-threatening illness. Palliative care has helped Deadra Gladden get her life back through symptom management and support from Samaritan Healthcare & Hospice, Marlton, N.J.
In May of 2014 Deadra, age 28, was in the hospital, feeling hopeless and in excruciating pain due to lupus, a disease she has been battling for over half her young life. Deadra's doctors told her family it was time to call hospice. But after consulting with a nurse from Samaritan Healthcare and Hospice, a palliative care team was brought in instead.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or were treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you may be eligible for compensation from a class action Settlement
A $190 million dollar proposed Settlement has been reached that offers payments to eligible members of The Levy Settlement Class.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7281851-dr-nikita-levy-patients-class-action-settlement/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials.
One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads.
The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Inc., and Eisai Inc. today announced the launch of Myths and Truths About Thyroid Cancer, an interactive, educational campaign designed to help dispel the myth that thyroid cancer is a “good cancer.” Because most thyroid cancers can be successfully treated, many are told if you are going to get cancer, thyroid cancer is the one to have, which has led to this misperception. However, whether successfully treated or not, the truth is all cancers can have a significant impact on a person’s life, beginning with the shock and distress of hearing the word “cancer” at diagnosis. In honor of Thyroid Cancer Awareness Month and the tens of thousands who receive a thyroid cancer diagnosis each year, Myths and Truths About Thyroid Cancer illustrates the life-changing realities of this disease.
“As a thyroid cancer survivor, I urge people to stop referring to thyroid cancer as the ‘good cancer,’ as I believe it downplays patients’ experiences,” said Joan Shey, founder of the Light of Life Foundation. “I hear time and time again from patients how difficult their diagnosis and treatment were and that their scars are more than skin deep. My hope is that this campaign can educate about the many types of thyroid cancer and change the thyroid cancer conversation.”
“Being part of a community of survivors is very important for people coping with thyroid cancer,” said Gary Bloom, thyroid cancer survivor and co-founder and executive director of ThyCa: Thyroid Cancer Survivors’ Association. “ThyCa takes this to heart, which is why we are proud to provide support and resources to the thyroid cancer community. We also know more needs to be done to elevate awareness of thyroid cancer and what patients need in terms of support for the rest of our lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7595951-eisai-thyroid-cancer-myths/
Many people think being on hospice means lying in a bed, barely conscious. However, this perception is not an accurate one. Many hospice patients' final moments are spent enjoying quality time with family and friends and creating special moments and memories. This would not be possible without the help of hospice.
The mission of hospice is to provide specialized care for patients in the final weeks and months of life and their families. More simply, hospice care supports living one’s life to the fullest with dignity regardless of how much time remains.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
